It's difficult to post on this board due to the la
Post# of 9122
(Total Views: 488)
Posted On: 03/05/2017 1:21:09 PM
It's difficult to post on this board due to the lack of knowledge of some of the other posters on medical aspects of the NanoLogix technologies and also the descent into politics after November.
To clarify to Matt, who obviously doesn't understand the evolution of the diagnostic technologies from Nano:
The Hindawi paper was not about a clinical trial, which would have involved "intervention in treatment" using the BNF western blot variant technology used to test 350+ patient samples. It was a study. No intervention (treatment) was performed based upon the results. In subsequent press releases or updates the logic and justification of the development of the modified ELISA N-Assay diagnostic was explained to us --- N-Assay is more sensitive, accurate, specific, and computer readable through the use of a standard microtiter plate reader, BNF is not, etc. It appears that NanoLogix then abandoned the BNF in favor of a much superior technology that is usable with standard in-situ lab equipment and techniques.
The proposed time and sensitivity study/trial is apparently being evaluated by those who will undertake that effort. It is not something that would be under negotiation with NanoLogix, but would be discussed amongst those who did the initial development ( the Faros, et al) and whomever showed interest at the CAOG annual meeting where the N-Assay was presented.
The individuals who have interest either have or will develop the proposal for the study/trial and then submit that proposal to their respective Institutional Review Boards (IRB) for acceptance and approval. Once approved, the study/trial will be registered with the FDA. Then the work occurs. Once completed, the results are compiled and then submitted to a peer reviewed journal for publication. The results are then available for marketing purposes.
As for the other statement wondering about sales before the above outlined work, my read of the latest couple of updates shows that to be exactly what has been happening with that large client.
Every negative post plays into the hands of the bashers. Every positive or simply explanatory post is NOT a pump.
Scott
To clarify to Matt, who obviously doesn't understand the evolution of the diagnostic technologies from Nano:
The Hindawi paper was not about a clinical trial, which would have involved "intervention in treatment" using the BNF western blot variant technology used to test 350+ patient samples. It was a study. No intervention (treatment) was performed based upon the results. In subsequent press releases or updates the logic and justification of the development of the modified ELISA N-Assay diagnostic was explained to us --- N-Assay is more sensitive, accurate, specific, and computer readable through the use of a standard microtiter plate reader, BNF is not, etc. It appears that NanoLogix then abandoned the BNF in favor of a much superior technology that is usable with standard in-situ lab equipment and techniques.
The proposed time and sensitivity study/trial is apparently being evaluated by those who will undertake that effort. It is not something that would be under negotiation with NanoLogix, but would be discussed amongst those who did the initial development ( the Faros, et al) and whomever showed interest at the CAOG annual meeting where the N-Assay was presented.
The individuals who have interest either have or will develop the proposal for the study/trial and then submit that proposal to their respective Institutional Review Boards (IRB) for acceptance and approval. Once approved, the study/trial will be registered with the FDA. Then the work occurs. Once completed, the results are compiled and then submitted to a peer reviewed journal for publication. The results are then available for marketing purposes.
As for the other statement wondering about sales before the above outlined work, my read of the latest couple of updates shows that to be exactly what has been happening with that large client.
Every negative post plays into the hands of the bashers. Every positive or simply explanatory post is NOT a pump.
Scott
(10)
(0)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼